Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Cancer -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (46)	5/12/2001 6:59:44 PM
From: Miljenko Zuanic	Respond to of 1840

No, I do not think that FDA will turn them down. However, it may put restriction on label and promotion until further data become available. Tarceva data for refractory NSCLC (monotherapy) are very good and seams that chance for promising first-line combination therapy are now much bigger. It will be interesting to see Iresa data for the some indication (it is their registration trial, now looks very reasonable approach). Miljenko PS: Link was mistake. AltaRex is going after sub-group, so it is not that positive.